EU IVDR Milestone: Cancer Biomarker Test First To Get A Companion Diagnostic CE Marking
Executive Summary
A major milestone has been reached in the EU after a cancer biomarker assay became the first product to receive a companion diagnostic certificate in the context of the EU In Vitro Diagnostic Regulation.
You may also be interested in...
EU Explains Steps Sponsors Must Take When Using Companion Diagnostics In Drug Development
A new Q&A document from the European Medicines Agency outlines the key steps that pharma companies should take when using companion diagnostics in clinical trials, and the information it expects to see in marketing authorization applications.
Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests
UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.